Archive for category: Incubator

A full house presented itself when Inven2 pitched 8 of their most promising cancer research projects at Oslo Cancer Cluster Incubator June 12th.

In total approximately 60 people gathered inside Oslo Cancer Cluster Innovation Park, and among the participants several experienced investors from other cancer projects.

— I’m positively surprised that so many potential and experienced investors found their way here today, commented Ole Kristian Hjelstuen, CEO at Inven2.

The event was the second in line of Inven2’s new pitching strategy, were they open up their projects at an early stage for potential investors and entrepreneurs with the will to transform the research into working companies.

— This shows that pitching is a good way to spread the word on the potential of our portfolio. The event today strengthens my belief that financing for our projects will be easier in the future, said Hjelstuen.

Eight Potential Treatments and Companies
Norway is among the very best when it comes to cancer research. Norwegian research has created top notch companies like Algeta, Nordic Nanovector, Ultimovacs and Zelluna Immunotherapy. Tuesdays  pitch proves that many more are on the horizon.

The eight-project presented at OCC Incubator are all exciting innovations that need financial backing and entrepreneurship to commercialize. The common denominator is a focus on modern treatments like immunology or precision medicine that are emerging as a result of what has been labelled “a breakthrough in cancer treatment” in later years.

Presentations of all eight projects available here.

The projects presented:

• Tankyrase inhibition in cancer therapy
• A new drug against Acute Myeloid Leukaemia (AML)
• Autologous anti-CD20 TCR-engineered T-cell therapy for recurrent Non-Hodgkin’s Lymphoma
• Lymphocyte Booster – Lymphocyte boosting growth medium for Adoptive Cell Therapy
• CD37 CAR for cancer immunotherapy
• IL-15 Immunotherapy – Fusion protein for immunotherapy of solid tumors
• Backscatter: A communication technology enabling colon-cancer screening

Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development.

Attention all Oslo Cancer Cluster and Incubator members.  Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 call them “presåkornkapital” meaning that the money is to serve as capital that stimulates the first stage of establishing a life science company. However, some criteria’s must be met to be eligible to apply. The application deadline is the 20th of February 2018.

Follow these criteria:

• Investment can constitute 3 million NOK per company
• Private investors must contribute with capital that at a minimum is equivalent with the Inven2-money “pre-såkornmidlene”.
• At least 50 percent of private capital must be from independent investors, investors that are not a founder or an employee of the company.
• The investment with “pre-såkorn” capital must be on equal terms with the private investments.
• Companies receiving the investment must at the time of investment be Norwegian and younger than five years counted from the registry date at The Brønnøysund Register Center
• Companies invested in must not be stock marked listed or large companies as defined in the EØS agreement state subsidy rules.
• Companies invested in must be innovative as defined by the EØS Agreement state subsidy rules.
• Investments can amount to 3 million NOK.

Be sure that your application contains the following:

• A short introduction of your company
• Business plan
• How the money will be used
• Explain how the matching money will be gathered
• A plan for the execution of the new equity

Application deadline: 20th of February.

Send the application to: olav.steinnes@inven2.com